EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Motion Sickness: Current Pharmacological Treatment Strategies and the Emerging Role of Tradipitant

Karol Jackowiak, Michał Kalisiak, Michał Kasznicki, Małgorzata Czechowska, Natalia Micek, Alicja Rogozińska, Jakub Łącki, Emilia Skrzypek, Mikołaj Kamela, Wiktor Beśka

Quality in Sport · 08.08.2026 · 66 · 74121

DOI: 10.12775/qs.2026.66.74121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Quality in Sport, online erschienen am 08.08.2026. Verfasst von Karol Jackowiak und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Motion sickness is a prevalent clinical syndrome triggered by sensory conflict, causing severe autonomic distress. While legacy treatments (anticholinergics and antihistamines) effectively manage symptoms, they cause a debilitating "pharmacological hangover" characterized by severe sedation and cognitive impairment.

Aim

This review evaluates tradipitant, a selective neurokinin-1 (NK1) receptor antagonist, investigating if targeting the Substance P pathway provides robust emetic protection without the functional decline of traditional therapies. Material and methods. A narrative review of PubMed, Google Scholar, Embase, ClinicalTrials, and FDA databases was conducted to analyze tradipitant's pharmacology, efficacy, and safety, emphasizing Phase 2 (Motion Sifnos) and Phase 3 (Motion Syros, Serifos) trials.

Results

Tradipitant competitively inhibits Substance P in brainstem emetic centers without binding to histaminergic or cholinergic receptors. Sifnos data demonstrated a 78% relative risk reduction in vomiting during rough seas. Syros confirmed significant reductions in primary and repeated vomiting across varying sea intensities. Somnolence rates remained low (6–12%), successfully decoupling anti-emetic protection from cognitive impairment, though mild-to-moderate nausea sometimes persisted.

Conclusions

Representing the first major motion sickness advancement in 40 years, tradipitant’s targeted, non-sedating profile preserves physical comfort and cognitive clarity. It addresses a critical unmet need for travelers, though further multi-environment research is warranted.

Zitieren

APA

Jackowiak, K., Kalisiak, M., Kasznicki, M., Czechowska, M., Micek, N., Rogozińska, A., Łącki, J., Skrzypek, E., Kamela, M., & Beśka, W. (2026). Motion Sickness: Current Pharmacological Treatment Strategies and the Emerging Role of Tradipitant. Quality in Sport, 66, 74121. https://doi.org/10.12775/qs.2026.66.74121

Vancouver

Jackowiak K, Kalisiak M, Kasznicki M, Czechowska M, Micek N, Rogozińska A, et al. Motion Sickness: Current Pharmacological Treatment Strategies and the Emerging Role of Tradipitant. Quality in Sport. 2026;66:74121. doi:10.12775/qs.2026.66.74121

BibTeX
@article{Jackowiak2026,
  author = {Jackowiak, Karol and Kalisiak, Michał and Kasznicki, Michał and Czechowska, Małgorzata and Micek, Natalia and Rogozińska, Alicja and Łącki, Jakub and Skrzypek, Emilia and Kamela, Mikołaj and Beśka, Wiktor},
  title = {Motion Sickness: Current Pharmacological Treatment Strategies and the Emerging Role of Tradipitant},
  journal = {Quality in Sport},
  year = {2026},
  volume = {66},
  pages = {74121},
  doi = {10.12775/qs.2026.66.74121}
}
Kostenlos starten →